Cancer stem cell mitochondrial machinery (CSC-MM)

Cancer stem cell (CSC) mitochondrial machinery encompasses the specialized metabolic and structural components of mitochondria that support the unique requirements of cancer stem cells, including self-renewal, survival under hypoxia, and resistance to conventional therapies. While many bulk tumor cells rely on aerobic glycolysis, CSCs often exhibit a metabolic dependency on oxidative phosphorylation (OXPHOS) and enhanced mitochondrial biogenesis to maintain their stemness and fuel metastatic spread (Viale et al., 2014, Nature). This machinery includes the electron transport chain (ETC) complexes, mitochondrial ribosomes (mitoribosomes), and the regulatory proteins governing mitochondrial fission, fusion, and mitophagy. Therapeutic strategies targeting this machinery aim to disrupt the energy supply and redox balance of CSCs, thereby sensitizing them to chemotherapy or directly inducing cell death (Lamb et al., 2015, Oncotarget). For example, certain antibiotics like tigecycline and doxycycline have been shown to inhibit mitoribosomes, selectively depleting CSC populations across various cancer types (Skrtic et al., 2011, Cancer Cell). However, the high degree of conservation between CSC mitochondria and those in healthy tissues remains a significant hurdle for clinical development, requiring precise therapeutic windows to avoid systemic toxicity.

Other names

Cancer stem cell mitochondriaCSC mitochondrial metabolismMitochondrial oxidative phosphorylation in CSCsMitochondrial biogenesis in cancer stem cells

Inhibition of mitochondrial protein synthesis (mitoribosomes), disruption of the electron transport chain (ETC) complexes, inhibition of mitochondrial oxidative phosphorylation (OXPHOS), and induction of mitochondrial-mediated apoptosis.